1. Home
  2. CAN vs CELC Comparison

CAN vs CELC Comparison

Compare CAN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAN
  • CELC
  • Stock Information
  • Founded
  • CAN 2013
  • CELC 2011
  • Country
  • CAN Singapore
  • CELC United States
  • Employees
  • CAN N/A
  • CELC N/A
  • Industry
  • CAN Semiconductors
  • CELC Medical Specialities
  • Sector
  • CAN Technology
  • CELC Health Care
  • Exchange
  • CAN Nasdaq
  • CELC Nasdaq
  • Market Cap
  • CAN 384.3M
  • CELC 327.3M
  • IPO Year
  • CAN 2019
  • CELC 2017
  • Fundamental
  • Price
  • CAN $0.60
  • CELC $11.62
  • Analyst Decision
  • CAN Strong Buy
  • CELC Strong Buy
  • Analyst Count
  • CAN 5
  • CELC 5
  • Target Price
  • CAN $2.90
  • CELC $30.80
  • AVG Volume (30 Days)
  • CAN 39.0M
  • CELC 148.5K
  • Earning Date
  • CAN 05-20-2025
  • CELC 05-14-2025
  • Dividend Yield
  • CAN N/A
  • CELC N/A
  • EPS Growth
  • CAN N/A
  • CELC N/A
  • EPS
  • CAN N/A
  • CELC N/A
  • Revenue
  • CAN $317,009,000.00
  • CELC N/A
  • Revenue This Year
  • CAN $166.98
  • CELC N/A
  • Revenue Next Year
  • CAN $32.96
  • CELC N/A
  • P/E Ratio
  • CAN N/A
  • CELC N/A
  • Revenue Growth
  • CAN 65.68
  • CELC N/A
  • 52 Week Low
  • CAN $0.53
  • CELC $7.58
  • 52 Week High
  • CAN $3.27
  • CELC $19.77
  • Technical
  • Relative Strength Index (RSI)
  • CAN 38.54
  • CELC 64.24
  • Support Level
  • CAN $0.63
  • CELC $10.50
  • Resistance Level
  • CAN $0.73
  • CELC $10.88
  • Average True Range (ATR)
  • CAN 0.07
  • CELC 0.62
  • MACD
  • CAN -0.01
  • CELC 0.05
  • Stochastic Oscillator
  • CAN 7.74
  • CELC 90.17

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: